LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

12.15 0.08

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

11.59

Max

12.21

Galvenie mērījumi

By Trading Economics

Ienākumi

1.4M

676K

Pārdošana

961K

18M

P/E

Sektora vidējais

48.528

110.024

EPS

-0.034

Dividenžu ienesīgums

0.48

Peļņas marža

3.67

Darbinieki

212

EBITDA

-3M

2.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+55.99% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.26%

Nākamie ieņēmumi

2026. g. 2. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-120M

248M

Iepriekšējā atvēršanas cena

12.07

Iepriekšējā slēgšanas cena

12.15

Ziņu noskaņojums

By Acuity

36%

64%

113 / 351 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 19. febr. 23:47 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 19. febr. 23:47 UTC

Tirgus saruna

Nikkei May Decline Amid Caution Over Potential U.S. Strike on Iran -- Market Talk

2026. g. 19. febr. 23:39 UTC

Iegādes, apvienošanās, pārņemšana

Swiss Re Corporate Solutions to Buy QBE Insurance's Global Trade Credit and Surety Business >SREN.EB

2026. g. 19. febr. 23:38 UTC

Peļņas

Samsung Fire & Marine Insurance 2025 Net KRW2.020T Vs. Net KRW2.077T >000810.SE

2026. g. 19. febr. 23:38 UTC

Peļņas

Samsung Fire & Marine Insurance 2025 Oper Pft KRW2.659T Vs. Pft KRW2.650T >000810.SE

2026. g. 19. febr. 23:38 UTC

Peļņas

Samsung Fire & Marine Insurance 2025 Rev KRW24.779T Vs. KRW22.657T >000810.SE

2026. g. 19. febr. 23:37 UTC

Tirgus saruna

Gold Edges Lower on Possible Position Adjustment -- Market Talk

2026. g. 19. febr. 23:34 UTC

Peļņas

Samsung Fire & Marine Insurance 4Q Net Profit Missed FactSet-Compiled Consensus

2026. g. 19. febr. 23:34 UTC

Peļņas

Samsung Fire & Marine Insurance 4Q Net KRW234.38B Vs. Net KRW207.88B >000810.SE

2026. g. 19. febr. 23:33 UTC

Peļņas

Samsung Fire & Marine Insurance 4Q Oper Pft KRW391.26B Vs. Pft KRW252.81B >000810.SE

2026. g. 19. febr. 23:33 UTC

Peļņas

Samsung Fire & Marine Insurance 4Q Rev KRW6.083T Vs. KRW6.297T >000810.SE

2026. g. 19. febr. 22:13 UTC

Tirgus saruna

Goodman's Lack of Earnings Upgrade 'Largely Timing Related' -- Market Talk

2026. g. 19. febr. 22:08 UTC

Peļņas

Fairfax Financial 4Q Rev $8.11B >FFH.T

2026. g. 19. febr. 22:07 UTC

Peļņas

Eldorado Gold 4Q EPS $1.19 >ELD.T

2026. g. 19. febr. 22:06 UTC

Peļņas

Centerra Gold: 2026 Consolidated Gold Production Expected 250,000 to 280,000 Ounces, Copper Production Expected 50M to 60M Pounds >CG.T

2026. g. 19. febr. 22:05 UTC

Peļņas

Eldorado Gold 4Q Adj EPS 63c >ELD.T

2026. g. 19. febr. 22:05 UTC

Peļņas

Eldorado Gold 4Q Rev $577.2M >ELD.T

2026. g. 19. febr. 22:04 UTC

Peļņas

Eldorado Gold 4Q Gold Sales 126,923 Ounces >ELD.T

2026. g. 19. febr. 22:04 UTC

Peļņas

Eldorado Gold 4Q Gold Production 123,416 Ounces >ELD.T

2026. g. 19. febr. 21:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2026. g. 19. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 19. febr. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 19. febr. 21:43 UTC

Peļņas

St Barbara 1H Underlying Profit A$1.3 Million Vs A$48.1 Million Loss Year Earlier

2026. g. 19. febr. 21:42 UTC

Iegādes, apvienošanās, pārņemšana

Palo Alto Networks Announces Offer to Purchase Relating to CyberArk Software Ltd.'s 0.00% Convertible Senior Notes Due 2030

2026. g. 19. febr. 21:42 UTC

Peļņas

St Barbara 1H Revenue A$128.8 Million, Up 32% On-Year

2026. g. 19. febr. 21:41 UTC

Peļņas

Correct: St Barbara 1H Net Loss A$249,000

2026. g. 19. febr. 21:40 UTC

Peļņas

St Barbara 1H Net Loss A$249 Million

2026. g. 19. febr. 21:39 UTC

Peļņas

Perseus Mining Reaffirms FY26 Production, AISC Guidance

2026. g. 19. febr. 21:37 UTC

Peļņas

These Stocks Are Today's Movers: Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, EPAM, and More -- Barrons.com

2026. g. 19. febr. 21:37 UTC

Peļņas

Century Aluminum Expects 1Q Adj EBITDA $215 M to $235 M >CENX

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

55.99% augšup

Prognoze 12 mēnešiem

Vidējais 19 USD  55.99%

Augstākais 19 USD

Zemākais 19 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

2

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

113 / 351 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat